Abstract
Due to the failure of chemotherapy and the only available vaccine, BCG, to control tuberculosis (TB) disease, there is an urgent need to develop new vaccines and therapeutics. The identification of correlates of immune protection or “biomarkers” will facilitate the rational design of vaccines and drugs for the prevention and clearance of TB infection. Although it is known that IFN-γ is essential for protective immunity, animal and human studies have found that IFN-γ alone is not sufficient for the prevention of TB disease. There is evidence that IL-23, a recently described member of the IL-12 family of cytokines, is important in the immuno-pathogenesis of TB. There is also evidence that regulatory T cells (Treg) are present in TB disease and that Treg may suppress effector T cell responses. In the last five years, clinical studies have been able to use Mycobacterium tuberculosis specific antigens, such as ESAT-6, to focus on recently infected, healthy contacts of TB patients in endemic countries. Advances in techniques such as multi-parameter flow cytometry and DNA microarray analysis will enable us to study these cohorts in great detail and facilitate the identification of immune correlates for the rational design of drugs and vaccines for the treatment and prevention of TB.
Keywords: Tuberculosis, correlate, biomarker, IFN-gamma, IL-4, IL-12, IL-23, FoxP3
Current Molecular Medicine
Title: Correlates of Immune Protection from Tuberculosis
Volume: 7 Issue: 3
Author(s): Helen A. Fletcher
Affiliation:
Keywords: Tuberculosis, correlate, biomarker, IFN-gamma, IL-4, IL-12, IL-23, FoxP3
Abstract: Due to the failure of chemotherapy and the only available vaccine, BCG, to control tuberculosis (TB) disease, there is an urgent need to develop new vaccines and therapeutics. The identification of correlates of immune protection or “biomarkers” will facilitate the rational design of vaccines and drugs for the prevention and clearance of TB infection. Although it is known that IFN-γ is essential for protective immunity, animal and human studies have found that IFN-γ alone is not sufficient for the prevention of TB disease. There is evidence that IL-23, a recently described member of the IL-12 family of cytokines, is important in the immuno-pathogenesis of TB. There is also evidence that regulatory T cells (Treg) are present in TB disease and that Treg may suppress effector T cell responses. In the last five years, clinical studies have been able to use Mycobacterium tuberculosis specific antigens, such as ESAT-6, to focus on recently infected, healthy contacts of TB patients in endemic countries. Advances in techniques such as multi-parameter flow cytometry and DNA microarray analysis will enable us to study these cohorts in great detail and facilitate the identification of immune correlates for the rational design of drugs and vaccines for the treatment and prevention of TB.
Export Options
About this article
Cite this article as:
Fletcher A. Helen, Correlates of Immune Protection from Tuberculosis, Current Molecular Medicine 2007; 7 (3) . https://dx.doi.org/10.2174/156652407780598520
DOI https://dx.doi.org/10.2174/156652407780598520 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
Current Pharmaceutical Design The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
Current Drug Metabolism Antimicrobial Activity of Diazenyl Derivatives: An Update
Current Topics in Medicinal Chemistry Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets 4-Oxothiazolidines with Exocyclic C=C Double Bond(s): Synthesis, Structure, Reactions and Biological Activity
Current Organic Chemistry Antibiotic Properties of Novel Synthetic Temporin A Analogs and a Cecropin A-Temporin A Hybrid Peptide
Protein & Peptide Letters The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine Synthesis and In Vitro Antimicrobial Evaluation of 4-alkyl/aryl-1-(3-phenoxypropionyl)-thiosemicarbazides
Letters in Drug Design & Discovery Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry Rip2: A Key Molecule that Regulates both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Ceric Ammonium Nitrate Catalysed Stereoselective Synthesis of β-Aminoketones Using 3-Aryl-4-Formylsydnones
Letters in Organic Chemistry Aiming at New Targets for the Treatment of Affective Disorders: An Introduction
Current Drug Targets Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
Current Medicinal Chemistry Drug Targets in Mycobacterial Sulfur Metabolism
Infectious Disorders - Drug Targets Can Mandated BCG Vaccine Promote herd Immunity against Novel Coronavirus? A Potential Solution at Hand to Tackle Covid-19 Pandemic
Current Immunology Reviews (Discontinued) Synthesis of Substituted -N-(5-((7-Methyl-2-Oxo-2H-Chromen-4-yl)- Methyl)-1,3,4-Thiadiazol-2-yl)-Benzamide Derivatives Using TBTU as Coupling Agent and their Evaluation for Anti Tubercular Activity
Letters in Organic Chemistry New Anti-Tuberculosis Drugs: Strategies, Sources and New Molecules
Current Medicinal Chemistry Synthesis, <i>In silico</i> and <i>In vitro</i> Analysis of Hydrazones as Potential Antituberculosis Agents
Current Computer-Aided Drug Design Slow-Onset Inhibition of 2-trans-Enoyl-ACP (CoA) Reductase from Mycobacterium tuberculosis by an Inorganic Complex
Current Pharmaceutical Design